Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells

Cancer Letters

Volumn 297, Issue 1, 2010, Pages 117-125

  Zheng, Hang ^a   Liu, Anling ^a   Liu, Bin ^b   Li, Minghui ^c   Yu, Hailang ^a   Luo, Xiaojun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Jiangsu Zeukov Pharmaceutical S and T Inc   (China)

Author keywords

Farnesyltransferase inhibitors; Mammalian target of rapamycin complex 1; Non small cell lung cancer; Ras homologue enriched in brain

Indexed keywords

CISPLATIN; LONAFARNIB; MESSENGER RNA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHEB PROTEIN; TIPIFARNIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MULTIPROTEIN COMPLEX; NEUROPEPTIDE; PIPERIDINE DERIVATIVE; PROTEIN; PROTEIN S6; PYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE; RHEB PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHOSPHORYLATION; PRENYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; LUNG NEOPLASMS; MONOMERIC GTP-BINDING PROTEINS; MUTATION; NEUROPEPTIDES; PHOSPHORYLATION; PIPERIDINES; PRENYLATION; PYRIDINES; QUINOLONES; RIBOSOMAL PROTEIN S6; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION; MULTIPROTEIN COMPLEXES; PROTEINS; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 77956229501     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.004     Document Type: Article

References (42)

1. A. Jemal, R Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M.J. Thun, Cancerstatistics 2008, CA Cancer J. Clin. 58 (2008) 71-96.
2. Carney D.N. Lung cancer-time to move on from chemotherapy. New Engl. J. Med. 2002, 346:126-128.
3. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
4. Dobashi Y., Suzuki S., Matsubara H., Kimura M., Endo S., Ooi A. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer. 2009, 115:107-118.
5. Sun X., Ritzenthaler J.D., Zhong X., Zheng Y., Roman J., Han S. Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha. Cancer Res. 2009, 69:6445-6453.
6. Dy G.K., Adjei A.A. Emerging therapeutic targets in non-small cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6:218-223.
7. Laplante M., Sabatini D.M. mTOR signaling at a glance. J. Cell Sci. 2009, 122:3589-3594.
8. Pal S.K., Figlin R.A., Reckamp K.L. The role of targeting mammalian target of rapamycin in lung cancer. Clin. Lung Cancer. 2008, 9:340-345.
9. La Monica S., Galetti M., Alfieri R.R., Cavazzoni A., Ardizzoni A., Tiseo M., et al. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem. Pharmacol 2009, 78:460-468.
10. Konstantinidou G., Bey E.A., Rabellino A., Schuster K., Maira M.S., Gazdar A.F., et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009, 69:7644-7652.
11. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 1996, 65:241-269.
12. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 1989, 49:4682-4689.
13. Adjei A.A. Blocking oncogenic ras signaling for cancer therapy. J. Natl. Cancer Inst. 2001, 93:1062-1074.
14. O'Regan R.M., Khuri F.R. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?. Endocr. Relat. Cancer 2004, 11:191-205.
15. Oh S.H., Kim W.Y., Kim J.H., Younes M.N., El-Naggar A.K., Myers J.N., et al. Identification of insulin-like growth factor binding protein-3 as a farnesyltransferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin. Cancer Res. 2006, 12:653-661.
16. Han J.Y., Oh S.H., Morgillo F., Myers J.N., Kim E., Hong W.K., et al. Hypoxia-inducible factor 1aand antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestivetract cancer. J. Natl. Cancer Inst. 2005, 97:1272-1286.
17. Basso A.D., Mirza A., Liu G., Long B.J., Bishop W.R., Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 2005, 280:31101-31108.
18. Pan J., Yeung S.C. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res. 2005, 65:9109-9112.
19. Aspuria P.J., Tamanoi F. The Rheb family of GTP-binding proteins. Cell Signal. 2004, 16:1105-1112.
20. Takahashi K., Nakagawa M., Young S.G., Yamanaka S. Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J. Biol. Chem. 2005, 280:32768-32774.
21. Hanker A.B., Mitin N., Wilder R.S., Henske E.P., Tamanoi F., Cox A.D., et al. Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene 2010, 29:380-391.
22. Buerger C., DeVries B., Stambolic V. Localization of Rheb to the endomembrane is critical for its signaling function. Biochem. Biophys. Res. Commun. 2006, 344:869-880.
23. Dong X., Yang B., Li Y., Zhong C., Ding J. Molecular basis of the acceleration of the GDP-GTP exchange of human ras homolog enriched in brain by human translationally controlled tumor protein. J. Biol. Chem. 2009, 284:23754-23764.
24. Mavrakis K.J., Zhu H., Silva R.L., Mills J.R., Teruya-Feldstein J., Lowe S.W., et al. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 2008, 22:2178-2188.
25. Nardella C., Chen Z., Salmena L., Carracedo A., Alimonti A., Egia A., et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 2008, 22:2172-2177.
26. Chun K.H., Lee H.Y., Hassan K., Khuri F., Hong W.K., Lotan R. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. 2003, 63:4796-4800.
27. Oh S.H., Jin Q., Kim E.S., Khuri F.R., Lee H.Y. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin. Cancer Res. 2008, 14:1581-1589.
28. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., et al. Tumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase in human tumor xenograft models in wap-ras transgenic mice. Cancer Res. 1998, 58:4947-4956.
29. Bai X., Ma D., Liu A., Shen X., Wang Q.J., Liu Y., et al. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007, 318:977-980.
30. Liu A.L., Zhang Z.M., Zhu B.F., Liao Z.H., Liu Z. Metallothionein protects bone marrow stromal cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation. Cell Biol. Int. 2004, 28:905-911.
31. Yamagata K., Sanders L.K., Kaufmann W.E., Yee W., Barnes C.A., Nathans D., et al. Rheb, a growth factor-and synaptic activity-regulated gene, encodes a novel Ras-related protein. J. Biol. Chem. 1994, 269:16333-16339.
32. Gromov P.S., Madsen P., Tomerup N., Celis J.E. A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rheb. FEBS Lett. 1995, 377:221-226.
33. Qiu Y., Liu X., Zou W., Yue P., Lonial S., Khuri F.R., et al. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res. 2007, 67:4973-4980.
34. Wang E., Casciano C.N., Clement R.P., Johnson W.W. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res. 2001, 61:7525-7529.
35. Gau C.L., Kato-Stankiewicz J., Jiang C., Miyamoto S., Guo L., Tamanoi F. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Mol. Cancer Ther. 2005, 4:918-926.
36. Adjei A.A., Davis J.N., Bruzek L.M., Erlichman C., Kaufmann S.H. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin. Cancer Res. 2001, 7:1438-1445.
37. Moasser M.M., Sepp-Lorenzino L., Kohl N.E., Balog A., Su D.S., et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA 1998, 95:1369-1374.
38. Cesario A., Catassi A., Festi L., Imperatori A., Pericelli A., Galetta D., et al. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. Clin. Cancer Res. 2005, 11:2026-2037.
39. Karp J.E., Flatten K., Feldman E.J., Greer J.M., Loegering D.A., Ricklis R.M., et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009, 113:4841-4852.
40. Jiang H., Vogt P.K. Constitutively active Rheb induces oncogenic transformation. Oncogene 2008, 27:5729-5740.
41. VanMeter A.J., Rodriguez A.S., Bowman E.D., Jen J., Harris C.C., Deng J., et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol. Cell Proteomics. 2008, 7:1902-1924.
42. Anagnostou V.K., Bepler G., Syrigos K.N., Tanoue L., Gettinger S., Homer R.J., et al. High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin. Cancer Res. 2009, 15:4157-4164.